Hypothesis: Arterial stiffening triggers a mechanotransduction cascade in vascular smooth muscle cells within the aorta and carotid arteries, fundamentally changing what extracellular vesicles these cells secrete. These vesicles carry senescent SASP components and tau nucleation intermediates that cross the blood-brain barrier through circumventricular organs and glymphatic entry points, seeding perivascular tau oligomerization years before cognitive symptoms appear.

Mechanistic Framework:

1. VSMC Senescence Induction: When pulse wave velocity increases, central artery walls experience abnormal cyclic stretch forces that exceed the physiological mechanosensing threshold of roughly 10-15% strain. This sustained biomechanical stress activates the DNA damage response in VSMCs, pushing cells toward p16^INK4a+ senescent phenotypes faster than age-matched controls would predict.

2. Altered Exosome Biogenesis: Senescent VSMCs show dysregulated ESCRT machinery, producing exosomes with shifted tetraspanin profiles (CD63+, CD81+) and cargo. These exosomes appear to carry truncated tau species missing the microtubule-binding domain, apolipoprotein E4 isoform-enriched lipoprotein particles, and SASP factors like IL-6, TGF-β, and MMPs at concentrations 3-5 times above baseline.

3. Perivascular Seeding Mechanism: The aortic arch and carotid bifurcation sit near brain regions with high perivascular fluid flux—the basal forebrain and hippocampus, for instance. Circulating EVs from stiffened arteries likely use apolipoprotein-mediated transcytosis across leaky neurovascular units, where their tau cargo seeds endogenous neuronal tau into oligomeric conformers.

4. Directionality Prediction: This framework predicts that midlife arterial stiffening (PWV 8-11 m/s) will precede detectable p-tau217 elevation by 5-10 years. People with elevated central artery PWV should show asymmetric tau PET signal in posterior cingulate and perihippocampal regions—essentially, perivascular drainage zones. Interventions like statins or RAS blockers that reduce PWV by more than 1 m/s should correspondingly lower circulating tau-bearing EV counts.

Testable Predictions:

• Cross-sectional: Adults aged 40-60 with cfPWV above 10 m/s should have detectable tau fragments in plasma exosome fractions, even when standard plasma p-tau217 reads negative.
• Longitudinal: Five-year changes in cfPWV should correlate more strongly with changes in plasma exosomal tau than with Aβ changes—distinct from total p-tau217.
• Intervention: Senolytic therapy (dasatinib plus quercetin, for example) should reduce circulating tau-bearing EVs in proportion to VSMC senescence markers in accessible tissue.

Integration with Existing Literature: This hypothesis weaves together the endothelial-NO dysfunction pathway with SASP-mediated elastin and collagen remodeling, extending the vascular-neurodegeneration coupling seen in PWV-neurodegeneration marker studies by proposing a specific propagative mechanism rather than just perfusion limitation.

Falsifiability: If plasma exosome tau cargo doesn't correlate with cfPWV in midlife adults, or if senolytic intervention reduces PWV without affecting neurodegeneration markers, this hypothesis would need to be discarded.

Novel Contribution: Rather than invoking perfusion impairment alone, this mechanism provides a direct molecular bridge linking arterial wall senescence to intracellular tau pathology. This might explain why African American populations show stronger PWV-neurodegeneration associations—higher baseline arterial stiffness burden—and supports early PWV-lowering interventions for dementia prevention.